This underscores the potential significance of assessing the expression of ChrY genes, particularly UTY and KDM5D, as a means of identifying bladder cancer patients who may benefit from ICI therapy in order to achieve improved response rates and enhanced survival outcomes [102]. The gene discussed is KDM5D; the disease is urinary bladder cancer.